医師による世論調査：がん専門医はAIががん治療の未来を形成すると見ている

がん治療の進歩に貢献するAIは、医療画像を人間よりも迅速かつ正確に分析することで、発見と診断を迅速化します。さらに、より高い精度により、AIは誤診を最小限に抑えることができます。ゲノムデータの分析を通じて、AIは治療効果を予測することで、がん治療の個別化を支援します。

ディープラーニングは、そのパターン認識能力を継続的に向上させることにより、悪性腫瘍と良性腫瘍をより正確に区別できるようになり、がん検出をさらに強化します。

当レポートでは、米国および欧州5カ国（フランス、ドイツ、イタリア、スペイン、英国）を拠点とする192人の腫瘍内科医を対象に、がん診断および治療計画におけるAIアルゴリズムの現在および将来の導入レベルを評価するための世論調査を実施しました。

レポートの内容

• AIを画像解析に応用することで、さまざまな種類のがんの検出や分類を改善することができる。現在、がん診断のための画像判読にAIソフトウェアをどの程度使用しているか
• 5年後、AIを用いた画像解析別、患者のがん診断のスピードが大幅に向上することに、どの程度同意するか
• ディープラーニングAIは病気の進行を予測することができる。現在、患者の治療プログラムを計画する際に、患者固有のリスク因子を推定するために、どの程度ディープラーニングAIを活用しているか
• AIアルゴリズムは、遺伝的抗がん剤感受性を特定するためのゲノム検査にも応用できる。現在、患者の個別化治療計画を策定するために、AIベースの臨床意思決定支援ツールをどの程度利用しているか
• 今後5年間で、AIが患者の治療計画に革命をもたらすことにどの程度同意するか

The backstory

Helping to advance cancer treatment, AI speeds up detection and diagnosis by analysing medical images faster and with more precision than can be done by humans. In addition, its greater accuracy allows AI to minimise false-positive diagnoses. Through the analysis of genomic data, AI helps personalise oncology care by predicting treatment response.

Deep learning further enhances cancer detection by continuously improving its pattern recognition capabilities, which allows it to more precisely distinguish malignant tumours from benign ones.

The physician view

FirstWord polled 192 oncologists based in the US and EUR5 (France, Germany, Italy, Spain and the UK) to assess current and future adoption levels of AI algorithms in cancer diagnosis and treatment planning.

Key Questions Answered:

• 1. AI can be applied to image analysis to improve detection and classification of different types of cancer. How often do you currently use AI software to help with interpreting images for cancer diagnosis?
• 2. Thinking ahead, how much do you agree that AI-based image analysis will significantly improve the speed of cancer diagnosis for your patients in five years' time?
• 3. Deep learning AI can predict disease progression. To what extent are you currently utilising deep learning AI to estimate patient-specific risk factors when planning treatment programmes for your patients?
• 4. AI algorithms can also be applied to genomic testing to identify genetic anticancer drug susceptibility. To what extent are you currently using AI-based clinical decision support tools to develop personalised treatment plans for your patients?
• 5. To what extent do you agree that AI will revolutionise treatment planning for your patients over the next five years?

Methodology

Dossier reports are developed from independent and concise analysis derived from original industry surveys and in-depth interviews with industry thought leaders. Reports analyse in detail significant developments and market trends that pharma executives need to understand if they are to manage the opportunities and challenges that lie ahead. The focus of each report is defined by a review of the secondary literature and any knowledge gaps identified. Based on this initial research, an evidence-based and expert-informed discussion guide is developed to ensure the research answers the most critical questions. Additionally, robust screening criteria are established to ensure that those interviewed are qualified in terms of their experience, knowledge and stature to speak on the topic.

What makes our reports different?

FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.